Trial Profile

A Phase 1b trial for MT-125 in glioblastoma patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2025 According to the Myosin Therapeutics Media Release, the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MT-125 to to initiate a Phase 1 study to evaluate MT-125 in combination with standard of care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma.
05 Mar 2025 New trial record
03 Mar 2025 According to the Myosin Therapeutics Media Release, company Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies, and This funding is pivotal as it will allow us to initiate multiple clinical trials this year, including this Phase 1b trial for MT-125 in glioblastoma patients.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com